A world where cardiovascular disease is no longer the leading cause of death – For patients. For healthcare providers. For society. That's the Amarin commitment. 

Globally, more than four out of five cardiovascular disease (CVD) deaths are caused by heart attacks and strokes. At least 38% of premature deaths from noncommunicable diseases in people younger than 70 years of age are due to cardiovascular disease.^1,2 19.8 million people died from CVDs in 2022, representing approximately 32% of all global deaths. Of these deaths, 85% were due to heart attack and stroke.² There is an urgent need for action to address this healthcare crisis.

Amarin is focused on reducing the CVD burden for patients and communities and to advancing the science of cardiovascular care around the world. In addition to the ground-breaking science and clinical development, we own and support a global branded product approved by multiple regulatory authorities based on a track record of proven efficacy and safety and backed by robust clinical trial evidence. Our commercialization model includes a direct sales approach in the U.S. and an indirect distribution strategy internationally, through a syndicate of reputable and well-established partners with significant geographic expertise, covering close to 100 markets worldwide. Our success is driven by a dedicated, talented, and highly skilled team of experts passionate about the fight against the world’s leading cause of death, CVD. Amarin is highly motivated to improve patient care while creating value for shareholders and society. These are just some of the ways we are changing the course of CVD. Learn more about Amarin and our history.

Amarin is built on a history of decisive actions. Read below for highlights of our history as a company committed to CVD prevention.

At Amarin, we’re focused on stopping cardiovascular disease (CVD) from being a leading cause of death. We believe that CVD patients, their loved ones, and society as a whole deserve a cardiovascular health management option that is reliable and effective in reducing the risk of CVD. There are people throughout the world, now and in the future, relying on us. We can give millions of patients the opportunity to change their lives for the better.